RESEARCH: HALOGENASES
FOLDING PROJECT #19208 PROFILE

Many medicines use halogens (like fluorine or chlorine). Adding these can be tricky and create harmful waste. Scientists are studying enzymes called halogenases that do this better and safer. This project uses computer models to predict how halogenases will add halogens to different molecules.

Note: This TLDR is a simplication and may not be 100% accurate.

Approximately 40 percent of drugs approved or currently in clinical testing contain halogens (F, Cl, Br, or I) as pharmaceutically active ligand substituents.

This makes the halogenation of chemical scaffolds an issue of particular interest to medicinal chemists when attempting to synthesize potential drug candidates.

Many of the current methods for halogenation are difficult to control the regioselectivity or produce toxic byproducts during the reaction.

Due to these issues; halogenases, a class of enzymes that catalyze highly regioselective halogenation of various molecules in nature, have been studied as a means to improve existing halogenation methods with less toxic byproducts and higher regioselectivity of reaction.

By utilizing Relative Binding Free Energy calculations (RBFE) across a number of common organic molecule scaffolds, our goal is to better predict the probability and site of halogenation for various common chemical scaffolds across a number of halogenases.

---

halogens

Elements fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

Halogens are a group of elements in the periodic table known for their reactivity. In medicine and pharmacology, they are often used as substituents in drug molecules to modify their properties and activity.

---

ligand

A molecule that binds to a specific receptor or site on another molecule.

In pharmacology, a ligand is a molecule that interacts with a target, such as a protein or receptor. This interaction can trigger various biological responses.

---

medicinal chemists

Scientists specializing in the design, synthesis, and development of drugs.

Medicinal chemists are experts in the field of drug discovery. They use their knowledge of chemistry and biology to create new medications that can treat diseases.

---

halogenation

The process of introducing a halogen atom into an organic molecule.

Halogenation is a common chemical reaction used in the pharmaceutical industry to modify the properties of drug molecules. It involves adding a halogen atom, such as fluorine or chlorine, to an organic compound.

---

regioselectivity

The ability of a chemical reaction to preferentially form one specific isomer over others.

Regioselectivity refers to the preference of a chemical reaction to produce one particular product over other possible isomers. This selectivity is important in drug synthesis to ensure the formation of the desired active compound.

---

byproducts

Unwanted substances produced as a result of a chemical reaction.

Byproducts are often formed during chemical reactions alongside the desired product. In pharmaceuticals, minimizing byproduct formation is crucial to ensure drug purity and safety.

---

halogenases

Enzymes that catalyze the regioselective halogenation of molecules.

Halogenases are enzymes found in nature that can introduce halogens into organic molecules with high precision. They offer a sustainable and environmentally friendly alternative to traditional halogenation methods.

---

Relative Binding Free Energy (RBFE)

An energy-based method for predicting the binding affinity of molecules.

RBFE calculations are used to predict how strongly a molecule will bind to another target. This information is valuable in drug discovery as it can help identify potential drug candidates.